Product Code: 02-FUSION-26
From £765.00 Early Bird
Early Bird Deadline: 31/01/2026
Deadline to order: 28/02/2026
Fusion gene testing for fusions relevant to therapy (ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, or FGFR3) for solid cancers (FFPE)
Fusion gene testing in FFPE tissue, for a range of clinically significant fusion variants, involving the following genes: ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, or FGFR3.
NGS, rtPCR
English, French, German, Italian, Spanish
FFPE
No
September 2026
September - November 2026
May - June 2027
You can complete purchase on our secure partner site.
The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.
Three mock clinical cases with matching samples will be provided (1x 10um FFPE section). Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results. Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test samples according to their routine strategy, to return a clinical report, and to complete the data collection form. No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
